pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP240909
Phase 3 · small molecule · Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
APHP240909 for Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP240909
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
- Status
- active
- Trials
- 1